Drug Trial Radar · NCT00106340
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,118
Actual
Start
Mar 2005
Primary completion
May 2008
Study completion May 20, 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 23, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 73 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Conditions
- Diabetes Mellitus, Type 2
Interventions
vildagliptinDrug
glimepirideDrug
MetforminDrug
Vildagliptin matching placeboDrug
Glimepiride matching placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to HbA1c >8%Time frame: 2 year
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Pharmaceuticals
East Hanover, New Jersey
Investigative Centers
Nuremberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.